- Current report filing (8-K)
May 06 2009 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported):
May 6, 2009
|
SUNESIS
PHARMACEUTICALS, INC.
|
|
(Exact
Name of Registrant as Specified in its
Charter)
|
|
Delaware
|
000-51531
|
94-3295878
|
|
(State
or Other Jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
|
395
Oyster Point Boulevard, Suite 400
South
San Francisco, California
|
94080
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(650) 266-3500
|
Not
Applicable
|
|
(Former
Name or Former Address, if Changed Since Last
Report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
2.02.
|
Results
of Operations and Financial
Condition.
|
On May 6,
2009, Sunesis Pharmaceuticals, Inc. issued a press release announcing its
financial results for the three months ended March 31, 2009. A copy of the press
release
is furnished
herewith as Exhibit 99.1 and incorporated herein by reference.
The press
release is furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject
to the liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained herein and in the
accompanying exhibit shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by Sunesis Pharmaceuticals,
Inc., whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
|
Item
9.01
|
Financial Statements and
Exhibits.
|
|
(d) Exhibits
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press
release, dated May 6, 2009, entitled “Sunesis Reports Financial Results
for the First Quarter 2009.”
|
* * * * *
* * * *
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Dated: May
6, 2009
|
|
|
SUNESIS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Eric
Bjerkholt
|
|
|
|
Eric H.
Bjerkholt
|
|
|
|
Senior Vice President, Corporate
Development and Finance, Chief Financial
Officer
|
EXHIBIT
INDEX
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press
release, dated March 31, 2009, entitled “Sunesis Reports Financial Results
for the First Quarter 2009.”
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024
